EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! (Seite 1122)

[wohinistmeinGeld]

kein Geld mehr zum Nachkaufen
hab nur 3500 St

[chachabings]

Finde es echt geil das ich das nochmal erleben darf Psi für 0,5... zu bekommen .
Bissl warte ich noch und schlage dann erneut zu .
Der Laden ist astrein , gefällt auch gut das sie mehrere
lohnende Biosilikon Vermarktungsstrategien in der Erforschung haben.
PS.: Habt ihr schon mal von Ernst & Young gehört ???
Das sind die mit größten Wirtschafts und Bilanzprüfer weltweit !!
Die sind nicht gerade preiswert und nehmen garantiert keine Klitschen in Ihren Kundenstamm auf !!!
So jetzt kommt die Ostereiersuchfrage:
Welches Nanotech Unternehmen hat Ernst & Young geprüft ???
Noch Fragen??
Also Kaufen Marsch , Marsch

CHACHA

[lustigerBosniak]

hallo schwabday,

läuft gut z.Zt.. bist auch bei psivida dabei ? sollte sich bald fett lohnen !

gruss

[biotech_nett]

Hallo Leute,

habe heute nochmal meine Psividia aufgestockt nachdem ich die lange gehaltenen Biophan verkauft habe, dachte jetzt ist es steuerfrei und der kurzfristige Anstieg rechtfertigt den Ausstieg, doch wohin mit der Kohle???

Die Lösung: - nochmal Psividia nachkaufen

- Warum? - positive Testergebnisse
- bester Leumund aufgrund der guten Kontakte
- glaube die Reg. of England ist noch investiert
- wenn es jetzt mal zu laufen anfängt will ich auch die Luft da oben schnuppern - soll gesund sein!

Bin zwar sonst nicht so gut im Thread schreiben und lese lieber Euere klugen Kommentare, doch ich bin stets an Neuigkeiten und Einschätzungen interessiert.
Danke!

[schwabday]

Hallo lustigerbosniak.

Hast ja zur Zeit ein glückliches Händchen

Gruss schwabday

[lustigerBosniak]

interessanter anstieg in den letzten stunden...

[mlolo]

@brunnen

wo denn? wann denn?ich seh nix!
kommt schon

[brunnenmann]

Psivida wird in der neuesten Börse-Online als Top-Pick im Nano-Bereich zum Kauf empfohlen.

Es geht wieder aufwärts!!!

[Konsole]

@Redclaw
Ich würde das etwas differenzierter sehen: Die armen Kassenpatienten bekommen BAY43-9006 und die Privatversicherten Brachysil. Ist alles eine Frage des Geldes.

[alexis74]

SHAREHOLDER UPDATE
March 2005

Dear Shareholder,

The past six months has been a busy and exciting period for pSivida with a number of
significant events occurring throughout this period.
In January your Company became truly global with pSivida listing on NASDAQ’s
National Market joining only eleven other Australian companies listed on one of the
world’s premier capital markets. With its NASDAQ listing completed your Company is
actively seeking to increase its presence and
capabilities in the US, the world’s most important
pharmaceutical and capital market. pSivida is
looking to appoint a US based CEO and Business
Development executive to assist with accelerating
the commercialization efforts for BioSiliconTM.
The awareness of pSivida in the US has been
steadily growing with increasing coverage in USbased
investor newsletters and industry
publications such as NanoBiotech News and the
Forbes/Global Nanotech Report. pSivida has also
been asked to present at upcoming investor based
conferences in March and April following a
successful presentation at the Brean Murray & Co
Annual Institutional Investor Conference in New
York in early February. Your Company is currently
in the US conducting a series of investor seminars
for both retail and institutional investors in an effort
to increase US-based investment in your Company.
Importantly your Company also continues to make excellent progress with the
development of its lead product BrachySilTM, for the treatment of inoperable primary liver
cancer by effectively delivering radiation directly to the tumor. Further interim data
released in February from the current Phase IIa clinical trial showed that BrachySilTM led
to significant regression of tumors. The results revealed an average reduction in tumor
size of 80% with some small tumors disappearing completely. These results are
particularly pleasing given the significant level of tumor regression achieved despite the
low dose being administered in the trial. As one of the few available technologies that
deliver a radioisotope directly to tumours, BrachySilTM has also shown to be safe, a
problem associated with some other tumour-targeted treatments. Importantly no
treatment related adverse events were reported in these patients.

These studies represent a critical milestone in pSivida’s product development plans and
lay the foundations for the process leading to registration of BrachySil™, our lead
product. Following the completion of the Phase IIa trial your Company expects to
commence a dose profiling study and pivotal registration trials for the product during
2005. BrachySilTM is expected to be registered as an approved treatment for liver
cancer potentially as early as 2007.
In line with the broader strategy for the development of BrachySilTM your Company is
looking to significantly expand the use of BrachySilTM for other solid tumour cancers,
ultimately producing a pipeline of BioSiliconTM based oncology products. This strategy
will substantially broaden the market potential of the product well beyond the possibilities
for current brachytherapy and embolisation approaches. The selection of these
indications has resulted from considerable consultation with the Company’s Oncology
Advisory Panel and significant research into the potential market size and competitive
landscapes that exist for cancer treatment in these areas.
As a first step in this process and in parallel to the development of BrachySilTM for
primary liver cancer, your Company aims to commence a human clinical trial for a
second cancer indication such as pancreatic cancer, within the next year. Importantly a
manufacturing and supply chain compliant to worldwide regulatory guidelines has
already been established for BrachySilTM, eliminating a costly and time-consuming
component in the development of future BrachySilTM products.

Your Company is currently seeking and is in discussions with development and
marketing partners in an effort to maximise the future return to shareholders for
BrachySilTM. Your Company is seeking to share some of the risks and costs associated
with taking this product through to registration and ultimately to market, although we
have the expertise and financial capacity to take BrachySil TM to product registration
alone should we choose to do so.

Other recent milestones for pSivida include:
· The signing of a deal with a top five global pharmaceutical company to evaluate
pSivida’s BioSilicon TM technology for drug delivery. The undisclosed
pharmaceutical company will fund the evaluation of BioSiliconTM in the controlled
release of a number of compounds. It is expected that this deal is the first of a
number of potential similar deals to be signed with other pharmaceutical
companies during the year.
· The signing of an agreement with ITOCHU Corporation of Japan, to develop and
commercialise BioSiliconTM products in Japan and Asia. The Agreement is an
important one as ITOCHU is one of Japan’s largest companies and the deal
covers opportunities for production, distribution, direct investment, licensing and
co-operative development programmes as well as the development of entirely
new applications for BioSiliconTM.
· The creation of Australian based subsidiary AION Diagnostics Limited for a
planned future spin off, which will develop diagnostic applications for
BioSiliconTM. Your Company appointed Dr Anna Kluczewska as MD of AION.
In other news, pSivida appointed a new R&D Director. Dr Mark Parry-Billings is a former
Director of R&D at Innovata Biomed and has held senior roles at Schering Healthcare
(UK). The appointment allows Chief Scientific Officer, Dr Leigh Canham to concentrate
on strategic developments associated with BioSiliconTM including new manufacturing
methods, ‘smart devices’ and general technical support for your Company’s drug
delivery program.

Your Company’s UK based operations have grown substantially over the last 12 months
with a current staff of 22 including some 15 PhDs. This has been necessary to meet the
increasing commitments involving the later stage development projects we are currently
working on, to expand our BioSiliconTM technology platform especially in drug delivery,
including the work for the undisclosed top five global pharmaceutical company and also
to support some of our other collaborative programmes.
pSivida has also strengthened its patent positions with a new European patent granted
for ’Biomirrors’, a novel form of BioSiliconTM that can be used in the blocking of light as a
means to protect the skin from harmful UV rays. In addition a European patent was
granted for the oral delivery of BioSiliconTM and, in the US, a patent was granted for
silicon fabricated products which overcomes the problems normally associated with the
damage to circuits caused by high temperature welding.
Importantly your Company’s focus remains the application of BioSilicon TM in controlled
release in drug delivery, exploiting this truly unique biomaterial’s many wonderful and
exciting properties. We have been using a similar consultative process to that which
we employed with BrachySilTM, consulting clinicians and market researchers to explore
other potential drug delivery applications for our technology. We are planning and
progressing the necessary pre-clinical studies which will enable us to embark on these
with a minimum of delay.

Updates on the progress of the top five global pharmaceutical company’s evaluation of
BioSiliconTM for drug delivery are expected throughout the year. It remains the
Company’s expectation that on the basis of successful outcomes from this, and other
similar evaluations that we expect to be carrying out, it will be in a position to secure
licensing agreements for the use of BioSiliconTM in delivering drugs for partner
companies in the pharmaceutical and biotechnology sectors.
pSivida has had an excellent start to 2005. We at pSivida thank you for your continued
support and look forward to achieving milestones such as the completion of the Phase
IIa trial and the commencement of pivotal registration trials for BrachySilTM as well as
further strengthening of the Company’s patent position, a growing international profile
and the maturation of your Company’s planned spin out, the newly created AION
Diagnostics.

Yours Sincerely,

Gavin Rezos,
Managing Director
pSivida Limited